Meta-analysis of alternate autologous vein bypass grafts to infrapopliteal arteries  by Albers, Maximiano et al.
Meta-analysis of alternate autologous vein bypass
grafts to infrapopliteal arteries
Maximiano Albers, MD, PhD,a Marcello Romiti, MD, PhD,a Francisco Cardoso Brochado-Neto, MD,
PhD,b and Carlos Alberto Bragança Pereira, PhD,b Santos and São Paulo, SP, Brazil
Background: Several studies have described acceptable results for infrapopliteal bypass surgery that uses an autogenous
vein other than the greater saphenous vein but is still no reliable prediction of outcomes. The objective of this study was
to use meta-analysis to assess the long-term outcomes after infrapopliteal bypass grafting done with alternate autologous
veins.
Methods: Studies published from 1982 through 2004 were identified from electronic databases and pertinent original
articles. Thirty-two series were selected, all of which had used survival analysis and had reported a 1-year graft patency
rate, with at least 15 bypasses. An interval success rate was calculated for each month in each series of grafts by using data
from life tables, survival curves, and texts. Monthly success rates were combined across series to obtain a pooled estimate
of success for each month. Pooled survival curves were then constructed for graft patency and foot preservation.
Results: The 5-year pooled estimates were 46.9% (95% confidence interval [CI]  35.5%-58.3%) for primary patency,
66.5% (95% CI 54.9%-78.2%) for secondary patency, and 76.4% (95% CI 68.0%-84.8%) for foot preservation. These
results were far superior to those reported for nonautologous grafts. Intensive duplex surveillance had a favorable impact
on graft patency and foot preservation. No publication bias was detected.
Conclusions: When the greater saphenous vein is unavailable, alternate autologous veins are preferable to other graft
materials in bypass surgery to infrapopliteal arteries. ( J Vasc Surg 2005;42:449-55.)The preferred conduit for infrapopliteal bypass grafting
is the greater saphenous vein, but it remains unclear which
alternate graft should be used when this vein is unavailable
to the surgeon. Often a policy of using all-autogenous
tissue grafts has been adopted, but this implies harvesting
veins from distant sites and constructing spliced vein grafts.
Because the use of nonautologous grafts has the appeal of
reducing operating times and the need for multiple inci-
sions, the plausible superiority of using alternate autolo-
gous veins (AAV) needs proof. In the absence of such a
proof, nonautologous grafts have been used liberally, par-
ticularly in nonteaching hospitals.1
An ongoing randomized comparative trial has included
19 AAV grafts and 36 polytetrafluoroethylene (PTFE)
grafts to infrapopliteal arteries.2 Much time will elapse
before this trial ends, and the final answer will be restricted
to spliced vein grafts and cuffed PTFE grafts. In contrast, a
historical series from the same center has included more
than 500 AAV grafts.3 A meta-analysis of the many pub-
lished series of AAV grafts thus seems attractive, as it can
assess graft effectiveness rapidly and may allow informal
comparison with meta-analyses of studies on other alterna-
tives.4,5 The present meta-analysis estimated the long-term
outcomes after AAV bypass grafting to infrapopliteal arteries.
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Type of graft. AAV grafts consisted of one or more
segments of autologous vessels harvested from the upper or
lower extremities, except for the single-segment greater
saphenous vein. Autologous vessel thus meant an arm vein,
the lesser saphenous vein, remnants of the greater saphe-
nous vein, the superficial femoral vein, or the endarterecto-
mized superficial femoral artery.
Study identification. The senior author (M.A.)
searched the PubMed database for relevant articles pub-
lished from 1982 through 2004. The descriptor “infrain-
guinal bypass” retrieved 697 titles, in which several words
were searched, including “autogenous,” “autologous,”
“vein,” “arm,” “cephalic,” “basilic,” “saphenous,” “com-
posite,” and “spliced.” After reading the abstracts online,
55 articles were printed for complete reading. A similar
strategy identified two additional articles in the OVID
database. Finally, the reference list of each printed article
was searched for additional titles. Of the 32 articles that
finally contributed series for the meta-analysis (APPEN-
DIX, online only), 17 articles3,6-21 were identified from
databases and 15 articles22-36 were found in the reference
lists.
Criteria for inclusion. The articles included in this
meta-analysis satisfied the following criteria: (1) a mini-
mum of 15 AAV grafts inserted distally into an infrapopli-
teal artery, (2) a greater number of infrapopliteal than
femoropopliteal bypasses, when these procedures had not
been described separately, (3) the use of survival analysis to
describe the outcomes, and (4) a minimum follow-up of a
year, at least for some grafts. Although authors from three
different centers have published more than one study on
the subject,3,8-10,22,23 inclusion of the same bypass more
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and on other information from the text.
Outcomes.  The outcomes selected for meta-analysis
included primary patency (PP), secondary patency (SP),
and foot preservation (FP). Although PP and SP reflect the
fate of arterial reconstructions for different graft materials
better than FP, the latter outcome describes the fate of
revascularized limbs, which does not depend solely on graft
patency. Patency outcomes have generally been reported as
recommended.37 Primary-assisted patency has been rigor-
ously equal to SP in four articles11-13,28 but was assumed to
be equal to PP in another article that reported a large
difference between primary-assisted patency and SP.14 In
four instances,15,23,26,27 the general expression “cumula-
tive patency” was assumed to represent SP.
Published life tables provided PP data for nine series,
SP data for 11 series, and FP data for nine series. Life tables
obtained directly from the authors supplied data for all
three outcomes in five series. Survival curves that showed
numbers at risk for all intervals were used to obtain PP for
six series, SP for eight series, and FP for seven series.
Survival curves that omitted the numbers at risk described
SP in one article and all three outcomes in two articles that
reported cumulative estimates and standard errors to one
decimal place.
Data from the text were combined with a life table or
survival curve for another outcome to generate data for PP
in one series, data for SP in two series, and data for FP in
two series. Data from the text alone were used to assess PP
in two articles, SP in one article, and FP in three articles.
Abstracts of papers presented at scientific meetings de-
scribed PP for two series and SP and FP for another series.
Study quality. An ideal study should contain the rea-
sons for using alternate grafts, the rates of patients requir-
ing these grafts, life tables rather than graphs, the 1-month
follow-up interval, an account for loss to follow-up, and the
use of PP, SP, and FP. Of particular relevance is a link
between predictive variables and each life table. Other
relevant items include the rates of primary bypasses and
tissue loss, regimens of postoperative antithrombotic ther-
apy, the rate of grafts that enlarged or became infected, and
data on further bypasses. Therefore, a perfect study would
score 14, with a decrease of one point for each unmet require-
ment. The quality scores ranged from 3 to 14 (median, 9) f o r
the 32 series (APPENDIX, online only). The scoring sys-
tem used here has not been previously validated but was in
strict accordance to recommended standards for reports
dealing with lower extremity ischemia37 and was used in
two previous meta-analyses.4,5
Data extraction. Two authors (M.R. and F.C.B.N.)
retrieved the data from life tables and from survival curves
that showed the number of units at risk for all intervals,
whereas the senior author (M.A.) retrieved the data from
less complete survival curves and from texts. In 15 of 29 life
tables for FP, the number of limbs revascularized to treat
claudication was subtracted from the total number of limbs
at risk at time zero and from the number of limbs censored
at subsequent intervals. This ad hoc procedure assumed anull risk of amputation in the absence of critical ischemia.
Fourteen life tables for FP remained unmodified, 10 be-
cause all the limbs had critical ischemia and four because of
missing data for the clinical symptoms.
Meta-analysis of subgroups. AAV graft series were
classified according to the period in which the study was
published (before or after December 31, 1996), according
to quality score (smaller or greater than 8.5), and according
to the inclusion or not of femoropopliteal bypasses. Despite
missing data in several articles, subgroups were also formed
according to the predominance of single-length (n  13)
or multisegment (n  11) conduits and according to the
use of duplex scanning for postoperative graft surveillance,
whether intensive (n  16) or selective (n  7). In the
analyses of duplex surveillance, only series that described all
three outcomes were used and time zero for survival anal-
ysis was fixed at 30 days after bypass surgery to compensate
for possible differences in early outcomes before surveil-
lance was started.
Meta-analysis comparison of different graft materials.
Our meta-analysis was compared at yearly intervals to meta-
analyses for five different graft materials by using the 95%
confidence intervals (95% CIs), either published or calcu-
lated from published pooled estimates and their standard
errors. The graft materials compared included PTFE grafts,
umbilical cord vein allografts, cryopreserved arterial and
venous allografts, and cold-storage vein allografts.4,5
Statistical methods. A random-effects meta-analysis
combined the monthly hazard rates from single series to
yield a pooled estimate of success for each month of follow-
up. This was done for PP, SP, and FP. The product of
successive monthly pooled estimates of success then yielded
a pooled measure of cumulative success for each group or
subgroup. Within-study, between-study, and between-in-
terval variances calculated as previously reported reduced
the influence of study size and provided less precise pooled
estimates.5 At yearly intervals, a standard error was calcu-
lated for the pooled estimate and a 95% CI was deter-
mined.4,5 Nonoverlapping 95% CIs indicated a likely sig-
nificant difference between AAV grafts and nonautologous
grafts.
Sensitivity analysis. In sensitivity analysis, adjust-
ments were made in the original series, some of which were
also excluded selectively, publication bias was investigated,
and fixed-effects modeling was considered.
Bias was introduced in the meta-analysis because (1)
the original studies assumed independence between events
and loss to follow-up, (2) some series included a few
patients with symptoms of claudication alone, and (3) some
series contained bypasses to popliteal or pedal arteries.
Based on a published protocol,4 the following adjustments
were made to the original series: (1) the first month of
follow-up concentrated the differences in the risk of failure
attributable to clinical symptoms and the level of distal
anastomosis; (2) a relative risk of graft failure of 0.75 was
used for patients with claudication alone and for femoro-
popliteal bypasses; (3) a relative risk of graft failure of 1.14
was used for pedal bypasses; (4) a percentage of censored
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month, 47% from the second to the 6th month, and 18%
from the 7th to the 12th month was applied; and (5) 60% of
units considered as lost within the first year of follow-up
represented additional failures.
Because femoropopliteal bypasses and the symptoms of
claudication alone correlated moderately in the series in-
cluded in the meta-analysis of FP (Pearson r  0.49), the
sensitivity analysis used a relative risk of amputation of 0.85
rather than 0.75 for femoropopliteal bypasses in 15 series
for which claudicators were excluded ad hoc. Because fem-
oropopliteal bypasses and secondary bypasses correlated
moderately in the series included in the meta-analysis of SP
(Pearson r  0.54) and in the series included in the
meta-analysis of FP (Pearson r  0.46), the sensitivity
analysis for clinical symptoms, level of lower anastomosis,
and completeness of follow-up also reduced a possible
confounding effect of secondary bypasses.
Studies that reported “cumulative patency,” a study in
which the reported primary-assisted patency was assumed
to represent PP, and studies for which the life tables were
retrieved from texts or from survival curves that omitted the
number of units at risk were excluded selectively.
RESULTS
Studies included in the meta-analysis. Thirty-two
articles described a total of 2618 grafts (APPENDIX, on-
line only). The mean age and the prevalence rates of male
gender, arterial hypertension, diabetes, secondary bypasses,
and smoking habits were frequently omitted (Table I). The
overall prevalence rate was 5.1% for surgery in patients with
claudication alone (29 articles). In 18 articles, there were
81.9% femorodistal bypasses, 13.2% popliteal-distal by-
passes, and 8.5% of other configurations. The overall prev-
alence rate was 17.9% for bypasses to a popliteal artery (31
articles), which were placed above the knee (4.6%) and
below the knee (13.3%), and 14.6% for pedal bypasses (26
articles). The alternative autologous vessel used included
an arm vein in 28 studies, the lesser saphenous vein in 11
studies, the superficial femoral vein in two studies, and the
endarterectomized superficial femoral artery in one study.
Main meta-analyses. The 5-year pooled estimate of
success was 46.9% (95% CI  35.5%-58.3%) for PP, 66.5%
(95% CI  54.9%-78.2%) for SP, and 76.4% (95% CI 
68.0%-84.8%) for FP (Table II). The early mortality de-
scribed in 24 articles ranged from 0% to 14% (median, 2.1%;
overall rate, 2.6%), whereas the 1-year cumulative death
rate described in 15 articles ranged from 3% to 27% (me-
dian, 13.5%; overall rate, 12.8%). Half of the articles de-
scribed wound complications, but the data were not re-
ported with sufficient detail to allow meta-analysis. Graft
infection and late graft degradation were rarely described.
Meta-analysis of subgroups.  Meta-analysis revealed
differences in pooled estimates that varied from month to
month. The average of these differences, which was labeled
the mean monthly difference, favored recent series (3.2%
for PP, 4.0% for SP, and 5.7% for FP), series of better
quality (6.7% for PP, 3.9% for SP, but –1.1% for FP),predominant single-length graft series (3.0 % for PP, 2.2%
for SP, and 1.9% for FP), and series containing some
femoropopliteal bypasses (– 0.5% for PP, but 4.1% for SP
and 4.6% for FP). The comparison between 1296 intensive
surveillance grafts and 747 selective surveillance grafts used
the same series in assessing all three main outcomes and
fixed time zero at 30 days. The mean monthly difference
favored intensive surveillance series (11.7% for SP and 7.4%
for FP, despite –7.0% for PP). Extensive overlapping was
found in all the aforementioned comparisons. A summary
of the subgroup meta-analyses is also provided (Table III).
Sensitivity analysis. Adjustments for clinical symp-
toms, level of distal anastomosis, and completeness of fol-
low-up reduced the 5-year pooled estimates by 4.0% for
both PP and SP and by 5.0% for FP. When four studies that
reported “cumulative patency” were excluded, the 5-year
pooled SP decreased by 1.2%. When a study for which
primary-assisted patency was assumed to represent PP was
excluded, the 5-year pooled PP remained unchanged.
When series for which the life tables were retrieved from
Table I. Demographic and surgical variables for alternate
autologous vein series
Available data
Series with
no data
Grafts 2618 0
Median age (y) 68 (61-74) 10
Males 63% (46%-88%) 14
Hypertension 50% (17%-73%) 20
Diabetes mellitus 48% (19%-85%) 14
Smoking 71% (41%-88%) 16
Heart disease 56% (31%-88%) 20
Second bypass 60% (14%-85%) 14
Claudication 3% (0%-30%) 4
Single vein 62% (0%-100%) 3
Popliteal-to-distal bypass 7% (0%-100%) 14
Pedal bypass 5% (0%-35%) 5
Popliteal bypass 9% (0%-48%) 0
Year of publication 1997 (1982-2004) 0
Year of beginning 1988 (1969-1998) 0
Censored 1 y 29% (0%-68%) 0
Score of quality 9 (3-14) 0
The data are median (range).
Table II. Meta-analysis of alternate autologous vein graft
series
Mo PP (n  27) SP (n  30) FP (n  29)
1 92.1 (89.4-94.8) 95.8 (93.9-97.7) 96.7 (94.6-98.7)
3 85.7 (81.9-89.4) 92.1 (89.9-94.4) 94.1 (91.6-96.5)
6 77.6 (73.3-81.8) 88.0 (85.2-90.8) 91.7 (88.9-94.5)
12 67.6 (62.2-73.0) 82.2 (78.4-86.0) 88.4 (84.9-91.8)
24 59.6 (53.1-66.2) 76.7 (71.0-82.3) 84.9 (80.2-89.6)
36 55.8 (48.0-63.6) 73.5 (66.7-80.3) 83.5 (77.2-89.8)
48 50.6 (38.0-63.2) 69.6 (60.8-78.4) 81.2 (73.2-89.3)
60 46.9 (35.5-58.3) 66.5 (54.9-78.2) 76.4 (68.0-84.8)
n, number of series combined; PP, primary patency; SP, secondary patency;
FP, foot preservation.
Values are pooled estimates (95% confidence intervals).texts or from survival curves that omitted the number of
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increased by 6.6% for PP, 0.9% for SP, and 1.5% for FP.
Therefore, poor specification of the type of graft patency
did not introduce bias, and the inclusion of series that
reported poor quality survival data avoided overestimation
of the results in favor of AAV grafts. When the foregoing
adjustments and selective withdrawals were done simulta-
neously, the 5-year pooled estimate increased by 1.6% for
PP, 5.5% for SP, and 3.0% for FP.
For a study size of less than 50 grafts, the 1-year
estimate was higher than the 1-year pooled estimate in 7 of
16 series for PP, in 4 of 18 series for SP, and in 4 of 19 series
for FP, which did not indicate a bias toward the publication
of small series that showed better results.
Fixed-effects meta-analysis showed an absolute increase
in the 5-year pooled estimate of 2.6% for PP, 2.0% for SP,
and 1.7% for FP and a corresponding absolute decrease in
their standard errors of 0.8%, 2.2%, and 1.0%, respectively.
Meta-analysis comparison of different graft
materials. A summary of the characteristics of articles in-
cluded in previous meta-analyses can be found else-
where.4,5 In brief, studies of both peripheral allografts and
PTFE grafts were more recent than studies of umbilical
cord vein allografts. The median quality score ranged from
8.5 to 11.5 for different peripheral allograft series, was 7 for
PTFE series, and was only 5.5 for umbilical cord vein
allograft series. Femoropopliteal bypasses corresponded to
2.2% of PTFE grafts, 8.4% of peripheral allograft series, and
3.6% of umbilical cord vein allografts. Pedal bypasses cor-
Table III. Subgroup meta-analysis of alternate
autologous vein grafts according type of conduit, use of
duplex scanning for graft surveillance, and inclusion of
femoropopliteal grafts
Outcome/subgroup n 1 mo 1 y 2 y 3 y 4 y 5 y
PP/single-length 14 93.8 70.3 60.9 56.9 50.8 46.1
PP/multisegment 11 88.4 62.9 56.3 52.6 51.5 51.5
SP/single-length 15 97.1 84.2 78.0 75.4 69.7 64.3
SP/multisegment 12 93.3 79.4 74.2 70.5 69.9 69.9
FP/single-length 15 96.9 89.8 86.0 84.7 82.7 75.8
FP/multisegment 11 95.4 86.8 83.9 82.0 78.8 78.8
PP/intensive DS* 16 100.0 69.7 60.0 56.6 54.0 54.0
PP/selective DS* 7 100.0 78.2 70.6 66.4 59.2 53.5
SP/intensive DS* 16 100.0 88.4 83.3 80.4 78.8 78.0
SP/selective DS* 7 100.0 79.6 72.8 68.7 62.2 57.3
FP/intensive DS* 16 100.0 93.1 90.6 88.9 86.3 86.3
FP/selective DS* 7 100.0 88.5 83.0 81.3 78.7 71.5
PP/only infrapop 10 94.0 69.3 58.2 55.2 50.2 50.2
PP/other 17 91.2 66.7 59.8 55.8 50.6 46.3
SP/only infrapop 13 94.6 80.0 73.2 68.9 66.4 65.6
SP/other 17 96.3 83.2 78.2 75.4 70.7 66.2
FP/only infrapop 11 95.6 84.1 80.8 79.7 76.3 76.3
FP/other 18 97.1 90.0 86.5 85.0 83.1 76.2
n, number of series combined; PP, primary patency; SP, secondary patency;
FP, foot preservation; DS, duplex scanning.
Values are pooled estimated. Overlap of 95% confidence intervals was found
in all the comparisons.
*Zero time of follow-up was the 30th postoperative day.responded to 1.6% of PTFE grafts and 4.8% of peripheralallografts but were not done with umbilical cord vein
allografts.
When AAV grafts were used for reference, there was
overlapping of the 95% CIs of the pooled PP for PTFE
grafts (Fig 1). Meta-analysis of PP for other graft materials
was not possible. The 95% CIs of the pooled SP did not
overlap for PTFE grafts, umbilical cord vein grafts, and
cryopreserved vein allografts (Fig 2). The 95% CIs of the
pooled FP did not overlap for either PTFE grafts or umbil-
ical cord vein grafts (Fig 3), but there were several overlaps
for cryopreserved vein allografts.
The 95% CIs of all three pooled outcomes overlapped
for cryopreserved arterial allografts and cold-storage vein
allografts. For clarity, these outcomes were not displayed
graphically. For the same reason, meta-analysis of FP for
cryopreserved vein allografts was omitted (Fig 3).
DISCUSSION
Meta-analysis of medical studies as a statistical proce-
dure refines the synthesis of available data, thereby allowing
surgical decision making to be done more scientifically.
Meta-analysis also enhances patient information and con-
sent and promotes respect for autonomy. The surgical
literature is full of uncontrolled series, each of which rep-
resents a poor source of scientific evidence. However, the
meta-analysis of such series provides a better source of
evidence, particularly when randomized trials are rare, as is
the case for infrapopliteal revascularization.
This study and two related meta-analyses4,5 aimed to
determine the outcomes after bypass surgery to infrapopli-
teal arteries for different graft materials. As expected, the
AAV graft emerged as the most effective alternative to the
standard greater saphenous vein graft. Alternate veins are
structurally and functionally similar to the greater saphe-
Fig 1. Meta-analysis survival curve of primary patency for alter-
nate autologous veins (AAV) (black) and polytetrafluoroethylene
(PTFE) (gray). Bars are half the amplitude of 95% confidence
intervals.nous vein, with emphasis on the presence of a living endo-
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AAV grafts in terms of SP (Fig 2) and FP (Fig 3).
When the present meta-analysis and the meta-analysis
of PTFE grafts were compared, the difference in PP was
greater than 10% at 18 months and beyond, which seems
clinically relevant, but the 95% CIs overlapped at most
yearly intervals (Fig 1). However, this comparison is unfair
because intensive duplex surveillance will create a lower PP
curve for AAV than for PTFE, for which intensive surveil-
lance is not usually used. Perhaps selective surveillance AAV
grafts would provide a better comparison with PTFE grafts.
The difference in SP between these meta-analyses was of
Fig 2. Meta-analysis survival curve of secondary patency (SP) for
alternate autologous veins (AAV) (black), polytetrafluoroethylene
(PTFE) (gray), umbilical cord vein (orange), and cryopreserved
vein (blue). Bars are half the amplitude of 95% confidence intervals.
Fig 3. Meta-analysis survival curve of foot preservation (FP) for
alternate autologous veins (AAV) (black), polytetrafluoroethylene
(PTFE) (gray), and umbilical cord vein (orange). Bars are half the
amplitude of 95% confidence intervals.high clinical relevance and was likely significant. In themeta-analysis of FP, an ad hoc procedure applied to symp-
toms of claudication alone avoided bias in favor of AAV
grafts, but the difference in favor of these grafts remained
impressive and was still significant. Although the patency of
PTFE grafts may benefit from the use of adjunctive proce-
dures at the distal anastomosis, a corresponding improve-
ment in FP remains uncertain.4
Meta-analyses of SP for peripheral vessel allograft by-
pass grafts have shown excellent early outcomes followed
by poor mid-term outcomes.5 Mainly because of repeat
bypass surgery, the 5-year pooled FP was greater than 60%
for three series of cryopreserved artery allografts and ten
series of cryopreserved vein allografts, which is a gratifying
result. Because the median year of publication for articles
included in the meta-analysis was 1995 for the PTFE grafts
and 1997 for the cryopreserved allografts, these grafts
currently compete each other. Despite the inclusion of
patients with more advanced limb ischemia, meta-analysis
of three series of cold-storage vein allografts yielded a
5-year pooled FP close to 40%, still an acceptable result if
the transmission of viral infection were not a major con-
cern.5 Peripheral vessel allografts may be useful in overcom-
ing critical ischemia for a short time, when a pedal bypass is
indicated or when there is a greater risk of wound dehis-
cence.
A meta-analysis for 16 series of umbilical cord vein
grafts5 has shown a poor early SP, but the long-term SP has
been slightly superior to those obtained for peripheral
vessel allografts. The 5-year pooled FP has been an accept-
able 55%, which was nearly identical to the 5-year pooled
FP of 55.7% described for PTFE grafts. The meta-analysis
for umbilical cord vein grafts has mostly reflected historical
vascular practice (median publication year, 1986), but su-
perb outcomes from a modern series keep these grafts
among the current alternatives for distal bypass surgery.38
However, these grafts have not been used in very distal
bypass grafting.5
The marked superiority of AAV grafts over nonautolo-
gous alternatives may increase further with statin therapy39
and a more frequent use of angioscopy or duplex scanning
intraoperatively.18 Intensive postoperative graft surveil-
lance with duplex scanning, which has been in use for more
than a decade, and the aggressive treatment of failing grafts
sacrifice PP to increase SP in the hope of also relieving the
symptoms and increasing FP. However, the appropriate-
ness of intensive surveillance remains controversial because
the relief of symptoms is difficult to assess and because
intensive-surveillance studies in patients originally present-
ing with critical ischemia have sometimes omitted FP
rates.18 To avoid the latter problem, the subgroup meta-
analysis of graft surveillance was restricted here to studies that
described all three outcomes. An absolute risk-reduction of
major amputation estimated as 4.6% at 12months, 7.6% at 36
months, and 14.8% at 60 months (Table III) provided some
support for using duplex surveillance intensively after AAV
bypass grafting to the infrapopliteal area.
Subgroup meta-analysis according to the period of
publication and study quality was done mainly for com-
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recent series for all three outcomes and better quality
studies for both PP and SP, but not for FP. The type of
AAV conduit may be a promising predictor of graft pa-
tency, but only a few series have actually constituted dis-
tinct subgroups of single-segment or multisegment grafts.
The initially worse pooled outcomes for predominant mul-
tisegment grafts probably reflected technical difficulties,
whereas the greater stability in long-term follow-up may be
the result of better ultimate conduits.
The applicability of AAV grafts was not addressed, but
nonautologous grafts may rarely be necessary, even when a
single-length AAV graft is unavailable. Roddy et al3 de-
scribed 536 spliced AAV grafts and 130 prosthetic grafts,
which corresponds to a ratio of 4:1. Because the propo-
nents of prosthetic grafts have usually reported limited
experience with AAV grafts, it remains uncertain whether a
complete inventory of the available veins had been done. If
nonautologous grafts are rarely needed, provide inferior
outcomes, and often require the prolonged use of oral
anticoagulants, then the choice of such grafts must be fully
justified to be ethically acceptable.
A limitation in the methodology used here concerned
the use of statistical inference when comparing two pooled
survival curves. It was not possible to calculate the P values
or to construct the 95% CIs for the differences observed.
Therefore, overlap of the 95% CIs was the only indication
of the lack of significant difference. Conversely, nonover-
lapping 95% CIs indicated a significant difference. This
problem did not affect the main results of this study.
Bias was of small magnitude in this meta-analysis of
observational studies. Indeed, sensitivity analysis showed
that subjectivism in the assessment of patency outcomes
and the acceptance of a few studies with poorly described
survival data did not introduce bias. Furthermore, patients
with critical ischemia corresponded to 95% of the grafts at
risk. In addition, the graft material and the level of distal
anastomosis were mostly restricted by design, and the rates
of less favorable pedal bypasses and of possibly more favor-
able femoropopliteal bypasses were equivalent. The overall
study quality would have been greatly improved had the
authors of the original studies adhered to recommended
standards for reporting.37
The validity of the inferences from this meta-analysis is
strongly supported by internal and external evidence. The
studies reviewed adopted similar outcomes, used data of
acceptable quality, and reported high response rates. In
addition, the study design, particularly the inclusive entry
criteria, was compatible with real life and allowed adequate
sampling of a hypothetical population of studies. Finally,
random-effects modeling avoided overestimation and un-
due precision of the measured outcomes. In the absence of
bias and study invalidity, we conclude that AAV grafts
provide better outcomes than nonautologous grafts in by-
pass surgery to infrapopliteal arteries and should be used
preferentially in the absence of a usable greater saphenous
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Author Size IC (%)
2nd
bypass (%)
Popliteal/
pedal (%)
Single
vein (%) DS
Score of
quality Outcomes
Alexander et al11 51 22 ? 41/0 82  9 All 3
Armstrong et al18 89 0 85 24/8 74  13 All 3
Balshi et al19 36 0 65 42/? 72 – 9 All 3
Brochado-Neto et al28 35 3 46 31/20 66 – 12 All 3
Browning et al33 40 8 73 18/3 42  9 All 3
Calligaro et al35 45 0 ? 0/18 82  10 All 3
Chalmers et al32 42 2 80 36/0 29  11 All 3
Chang et al10 69 0 74 12/6 58  6 PP FP
Chew et al9 136 ? 58 0/12 0  12 All 3
Chew et al8 34 ? ? 0/? 100  8 All 3
Curi et al14 61 5 51 7/8 0 ? 9 All 3
Eugster et al13 86 16 ? 29/? 0  6 All 3
Faries et al24 520 2 53 27/35 70 – 10 All 3
Gentile et al12 133 0 ? 0/? ?  6 SP FP
Goyal et al29 21 0 14 0/0 100  13 All 3
Graham and Lusby27 37 5 ? 0/0 27 – 6 All 3
Halloran et al17 61 0 ? 0/20 59  6 All 3
Harris et al22 54 7 39 22/6 0 – 10 SP FP
Harris et al23 102 30 ? 48/5 100 – 8 All 3
Harward et al31 43 7 49 21/0 14  13 All 3
Hickey et al25 60 0 ? 0/0 38 – 4 SP
Hölzenbein et al6 120 3 83 23/7 75 ? 5 PP
Lovell et al30 36 14 64 0/0 ?  9 All 3
Osman et al7 43 ? 60 9/9 47  8 All 3
Ouriel36 21 0 29 0/0 100 ? 11 All 3
Presti et al20 30 0 17 0/3 0 – 14 All 3
Roddy et al3 536 0 ? ?/? 0  8 All 3
Schneider et al34 41 0 ? 0/20 ?  8 All 3
Schulman and Badhey15 16 0 ? 0/6 100 – 6 SP
Sesto et al21 35 17 50 29/0 66 – 9 All 3
Tisi et al16 42 5 64 12/0 70  7 All 3
Weaver et al26 43 ? ? 9/0 67 – 3 SP FP
IC, patients with intermittent claudication only; DS, intensive duplex surveillance; ?, not informed; PP, primary patency; SP, secondary patency; FP, foot
preservation.
